Merck, Gilead's failed Trodelvy lung cancer trial shows better China results

Gilead's Trodelvy failed its global phase 3 trial as a first-line treatment for non-small cell lung cancer, showing no overall survival benefit, but post-hoc analysis revealed significantly better outcomes in Chinese patients. This contrast raises questions about the translatability of China trial data to global populations and impacts perception of Merck's similar TROP2 ADC program partnered with China's Kelun-Biotech.

This Wire brief sits within Fusion42's coverage of Biotech.